CO-VANTAGE-DATA-CENTERS
13.12.2022 14:01:34 CET | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, announced today the construction of a second campus (JNB2) in Johannesburg, South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005272/en/
JNB11 facility on Vantage Data Centers' developing 80MW campus in Johannesburg, South Africa. The company is now developing a second campus 17 kilometers away. (Photo: Business Wire)
The JNB2 Isando campus is strategically located in Ekurhuleni, the greater Johannesburg Metropol’s trade and industry hub, and approximately 17 kilometers from Vantage’s growing JNB1 Midrand campus. JNB2 is sited near the OR Tambo International Airport and less than two kilometers from the NAPAfrica neutral Internet eXchange in a region that serves as the cloud on-ramp for a number of large technology companies.
“South Africa continues to be a cornerstone for Vantage’s EMEA growth outside of continental Europe,” said Antoine Boniface, president, Vantage Data Centers, EMEA. “Investing in a second campus is a testament to our commitment to the region and our customers who have business requirements to be in this high-demand market.”
The first building of the JNB2 campus will consist of a 20MW 355,000 square foot (33,000 square meters) two-story data center and will be operational in mid-2024. Vantage is repurposing a portion of an existing warehouse for the initial phase, reducing the embodied carbon of the development.
Sustainable Design
Many features of JNB2 are based on Vantage’s standardized campus blueprint, emphasizing sustainable construction practices. This includes offering renewable energy options through a recent Power Purchase Agreement with SolarAfrica, limiting carbon footprints, maintaining energy efficient operations with an industry-leading power usage effectiveness (PUE) and minimizing the use of water.
Power and Cooling
The first data center on the JNB2 campus will be cooled using a highly efficient, closed-loop chilled water system generated through air-cooled chillers. An integrated economizer capability will allow reduced compressor energy based on outside ambient temperature. This allows Vantage to take advantage of cooler seasonal temperatures to minimize resource usage. Customers will benefit from power provided by the Municipality of Ekurhuleni, combined with a dedicated on-site, high-voltage substation.
Security and Amenities
Campus security remains a priority for Vantage, and the company’s hallmark security measures include an on-site security operations center with 24x7x365 patrols, perimeter security, CCTV on all access points, and multi-level authentication and access controls for employees, customers and visitors.
This new data center will provide dedicated offices and workspaces, break areas, conference rooms, meeting spaces and secure storage areas.
JNB1 Expansion
On Vantage’s inaugural and award-winning 80MW campus in Midrand, South Africa, the company opened its first 16MW facility in July 2022, and continues expanding the development to meet customer demand. The next phase is under construction and is slated to be operational in early 2024.
For more information about Vantage’s global campus footprint, visit https://vantage-dc.com/data-center-locations/.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
